Proposed UPI MDR could add ₹1.2 crore annual cost for pharma distributor
A proposed 0.4% MDR on eligible merchant UPI payments above ₹2,000, capped at ₹300, could pressure low-margin retailers and distributors. MPC Pharma estimates a ₹40,000 daily cost, or about ₹1.2 crore annually, and may limit large UPI payments if the framework takes effect.
What happened
NPCI · Proposed MDR on high-value UPI merchant payments could materially raise payment costs for Indian low-margin retailers and distributors. MPC Pharma
Key facts
- 0.4% MDR on eligible P2M UPI transactions above ₹2,000
- ₹300 MDR cap
- ₹1 lakh monthly UPI QR receipts exemption for P2PM small merchants
- ₹5 flat MDR for specified sectors
- 0.02% MDR for capital-market transactions
- ₹1 crore daily UPI payments estimated by MPC Pharma
- ₹40,000 daily estimated MDR cost
- ₹1.2 crore estimated annual impact
- 2-3% business margin
- 13.3%-20% of gross profit
Why this matters
The policy shift could create partnership opportunities with banks, payment providers, and fintechs offering lower-cost acceptance or alternative settlement solutions for large-ticket merchants.
What to watch
- Final NPCI, RBI, Ministry of Finance, or government notification defining MDR rate, merchant categories, transaction threshold, cap, and effective date.
- Whether public subsidy or reimbursement is offered to banks/payment service providers, preserving zero-MDR acceptance for merchants.
- Clarification on treatment of P2M UPI versus RuPay credit-card-on-UPI, prepaid instruments, and business-to-business collections.
- Merchant association and pharmacy/distributor lobbying, especially evidence of UPI acceptance limits on transactions above ₹2,000.
- Monthly UPI ticket-size data and changes in large-value merchant UPI volumes after policy announcements.
- Payment aggregators' revised pricing, enterprise discounting, and settlement terms.
- Competitor actions on large-ticket UPI acceptance, invoice payment options, and customer-facing fees.
- Model UPI payment mix by ticket size, specifically the share of merchant collections above ₹2,000, before estimating earnings exposure.
- Prepare customer migration flows for high-value invoices: UPI-to-bank-transfer prompts, QR/payment-link routing, and accounts-receivable reconciliation controls.
- Renegotiate acquiring terms with banks and payment aggregators; seek volume-based MDR rebates, category exemptions, or capped monthly fees.
- Review whether payment-mode restrictions or surcharges are legally and commercially viable, with particular attention to drug-retail customer experience.
- Build MDR cost-recovery options into distributor margin negotiations, supplier schemes, and minimum-order-value policies.
- Accelerate digital collection alternatives for B2B customers, including direct bank mandates, virtual accounts, and credit-linked payment rails.